Regulus Therapeutics
RGLS
#7200
Rank
NZ$1.03 B
Marketcap
NZ$14.92
Share price
0.00%
Change (1 day)
448.75%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -NZ$79.77 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -NZ$84.46 Million a decrease over its 2023 earnings that were of -NZ$53.81 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -NZ$79.77 Million-5.55%
2024 -NZ$84.46 Million56.97%
2023 -NZ$53.81 Million6.51%
2022 -NZ$50.52 Million2.53%
2021 -NZ$49.27 Million93.59%
2020 -NZ$25.45 Million-15.41%
2019 -NZ$30.09 Million-64.46%
2018 -NZ$84.65 Million-33.26%
2017 -NZ$0.13 Billion-13.98%
2016 -NZ$0.15 Billion44.77%
2015 -NZ$0.11 Billion-1.63%
2014 -NZ$0.11 Billion203.6%
2013 -NZ$34.11 Million8.65%
2012 -NZ$31.39 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
NZ$14.23 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
NZ$0.81 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$20.71 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$27.58 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$13.07 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-NZ$0.21 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-NZ$0.22 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$2.23 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA